Brokers Set Expectations for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Iovance Biotherapeutics in a research report issued to clients and investors on Tuesday, February 24th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.54) EPS and FY2027 earnings at ($0.28) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. The business had revenue of $86.77 million for the quarter, compared to analysts’ expectations of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.09%.

A number of other equities research analysts have also issued reports on IOVA. Chardan Capital dropped their target price on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday. The Goldman Sachs Group restated a “sell” rating and set a $2.00 price objective on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Barclays raised their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Iovance Biotherapeutics Price Performance

Shares of Iovance Biotherapeutics stock opened at $3.83 on Thursday. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -3.42 and a beta of 0.76. The stock’s 50-day moving average is $2.67 and its 200-day moving average is $2.41. Iovance Biotherapeutics has a one year low of $1.64 and a one year high of $5.64.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of IOVA. Vontobel Holding Ltd. acquired a new stake in Iovance Biotherapeutics in the 3rd quarter valued at about $26,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Iovance Biotherapeutics during the third quarter worth approximately $27,000. Arcataur Capital Management LLC bought a new stake in Iovance Biotherapeutics in the fourth quarter valued at approximately $29,000. Granite Investment Partners LLC acquired a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at approximately $29,000. Finally, Motley Fool Asset Management LLC bought a new position in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $29,000. 77.03% of the stock is owned by institutional investors.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q4 results beat expectations (narrower loss, $86.8M revenue) with Amtagvi sales up ~33% and management pointing to improved margins and pipeline momentum. This is a primary earnings catalyst supporting the rally. IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
• Positive Sentiment: FDA approval and positive real‑world data for lifileucel (Amtagvi) have shifted the program from a pipeline bet toward commercial execution, increasing revenue visibility and investor enthusiasm. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test
• Positive Sentiment: Positive pilot sarcoma data (50% objective response rate in advanced soft‑tissue sarcomas) broadens Amtagvi’s potential label expansion and prompted immediate investor buying. This clinical readout is being treated as a material pipeline catalyst. Iovance Announces Positive Results for TIL Cell Therapy in Soft Tissue Sarcomas
• Positive Sentiment: Analyst sentiment is improving — Barclays raised its price target to $11 and Citizens JMP upgraded the stock — adding institutional validation to the move and supporting further upside potential. Analyst Coverage / Price Target Changes
• Positive Sentiment: Operational/volume story: coverage explaining a Philadelphia manufacturing/scale rationale helped investor confidence that commercial execution can improve, contributing to the weekly surge. Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
• Neutral Sentiment: Chardan trimmed its price target slightly (from $17 to $16) but kept a buy rating — a mixed signal (still bullish but slightly less aggressive). Chardan Lowers Price Target on Iovance
• Neutral Sentiment: Unusual options activity: a large one‑day increase in call buying was reported, signaling speculative bullish positioning but not confirming sustained fundamental buying. (Market flows can amplify moves.)
• Negative Sentiment: Short interest jumped ~24.8% in February to ~131.3M shares — ~36.9% of float — and a short‑interest ratio near 14.6 days. That raises potential for volatility (squeeze risk) but also indicates strong bearish positioning that could pressure the stock if fundamentals weaken.
• Negative Sentiment: Cash/runway and dilution risk remain material — analysts and sell‑side commentary flag that Iovance may need additional capital before Amtagvi generates steady cash flow, which could lead to future dilution. Seeking Alpha: Better Gross Margin And Faster Turnaround Support A Higher Floor

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.